Mexico Plasma Fractionation Market

Mexico Plasma Fractionation Market Overview:

The Mexico plasma fractionation market size reached USD XX Million in 2024. Looking forward, IMARC Group expects the market to reach USD XX Million by 2033, exhibiting a growth rate (CAGR) of XX% during 2025-2033. The growing demand for plasma-derived therapies, increasing incidence of immunodeficiency disorders, and expanding healthcare access are fueling the market growth. In addition to this, government support for blood plasma donation, continual advancements in fractionation techniques, rising investment by biopharmaceutical companies, improved supply chains, and enhanced patient access to critical plasma-based treatments are some of the major factors augmenting the Mexico plasma fractionation market share.

Mexico Plasma Fractionation Market Trends:

Expansion of Blood Donation Centers and Campaigns to Bolster Plasma Collection Efforts

Mexico is intensifying its national efforts to promote blood and plasma donation as part of a broader strategy to support domestic plasma fractionation initiatives. Notably, on September 5, 2024, Mexico's Ministry of Health launched the National Blood System to enhance blood donation efficiency and resource management across federal and state levels. This initiative aims to optimize the operations of over 530 blood banks, 4,500 transfusion services, and 450 collection centers, ensuring timely blood delivery, particularly to underserved regions. Additionally, the Ministry of Health and affiliated institutions like the Centro Nacional de la Transfusión Sanguínea (CNTS) are launching coordinated campaigns focused on public education, donor incentives (non-monetary), and community engagement to increase participation rates. Mobile collection units, university partnerships, and donor awareness programs are being scaled up, especially in urban centers like Mexico City, Guadalajara, and Monterrey. Furthermore, efforts are increasingly directed toward creating a culture of repeat donation, as frequent voluntary donors tend to provide higher-quality plasma with better traceability and safety profiles. This is essential to produce immunoglobulins and clotting factors that meet international standards. In line with this, campaigns and digital initiatives, including mobile apps and SMS-based donor follow-ups aimed at improving appointment scheduling and donor retention, are strengthening the market.

Rising Demand for Immunoglobulins Due to Autoimmune and Neurological Disorders

The demand for immunoglobulin therapies in Mexico is increasing significantly, driven by the growing prevalence of autoimmune conditions such as Guillain-Barré syndrome, primary immunodeficiency diseases, and chronic inflammatory demyelinating polyneuropathy. According to industry reports, as of March 29, 2024, there were 81 documented cases of acute flaccid paralysis, of which 34 were confirmed as GBS, with four fatalities linked to the condition. These figures underscore the critical role of immunoglobulin therapies, which remain a frontline treatment for GBS due to their ability to modulate immune responses and reduce nerve inflammation. This, in turn, is supporting Mexico plasma fractionation market growth. As diagnostic capabilities improve and awareness spreads among healthcare professionals and patients, there is a marked rise in therapeutic use cases for intravenous and subcutaneous immunoglobulins. Hospitals and specialty clinics are reporting a surge in prescriptions for these products, which are often critical for managing rare and chronic conditions. Additionally, clinical guidelines are updated to reflect emerging evidence supporting early and sustained immunoglobulin use in several indications. These shifts are pressuring both public procurement systems and private distributors to increase supply reliability. This trend is prompting investment in both domestic production and more secure import contracts, creating a competitive environment among suppliers seeking long-term institutional buyers.

Mexico Plasma Fractionation Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2025-2033. Our report has categorized the market based on product, sector, application, and end user.

Product Insights:

• Immunoglobulins
• Albumin
• Coagulation factor VIII
• Coagulation factor IX

The report has provided a detailed breakup and analysis of the market based on the product. This includes immunoglobulins, albumin, coagulation factor VIII, and coagulation factor IX.

Sector Insights:

• Private Sector
• Public Sector

A detailed breakup and analysis of the market based on the sector have also been provided in the report. This includes private sector and public sector.

Application Insights:

• Neurology
• Immunology
• Hematology
• Others

The report has provided a detailed breakup and analysis of the market based on the application. This includes neurology, immunology, hematology, and others.

End User Insights:

• Hospitals and Clinics
• Clinical Research Laboratories
• Academic Institutes

A detailed breakup and analysis of the market based on the end user have also been provided in the report. This includes hospitals and clinics, clinical research laboratories, and academic institutes.

Regional Insights:

• Northern Mexico 
• Central Mexico 
• Southern Mexico 
• Others 

The report has also provided a comprehensive analysis of all the major regional markets, which include Northern Mexico, Central Mexico, Southern Mexico, and others. 

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Mexico Plasma Fractionation Market Report Coverage:

Key Questions Answered in This Report:

• How has the Mexico plasma fractionation market performed so far and how will it perform in the coming years?
• What is the breakup of the Mexico plasma fractionation market on the basis of product?
• What is the breakup of the Mexico plasma fractionation market on the basis of sector?
• What is the breakup of the Mexico plasma fractionation market on the basis of application?
• What is the breakup of the Mexico plasma fractionation market on the basis of end user?
• What is the breakup of the Mexico plasma fractionation market on the basis of region?
• What are the various stages in the value chain of the Mexico plasma fractionation market? 
• What are the key driving factors and challenges in the Mexico plasma fractionation market?
• What is the structure of the Mexico plasma fractionation market and who are the key players?
• What is the degree of competition in the Mexico plasma fractionation market? 

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the Mexico plasma fractionation market from 2019-2033.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the Mexico plasma fractionation market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the Mexico plasma fractionation industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.